Indications and Usage

Romidepsin is FDA approved for the treatment of patients with cutaneous T-cell lymphoma (CTCL) who have received at least one prior systemic therapy and treatment of patients with peripheral T-cell lymphoma (PTCL) who have received at least one prior therapy.

Side effects needing medical attention

Excessive nausea or vomiting; abnormal heartbeat; chest pain or shortness of breath; unusual bleeding; fever; cough; flu-like symptoms; burning on urination; muscle aches; worsening of skin problems; persistent diarrhea; loss of appetite; tiredness; infections; abdominal pain; low levels of magnesium, calcium, potassium or sodium in blood; low blood cell counts; changes in taste; constipation; hypotension; itchy skin; electrocardiogram T-wave changes; hyperglycemia.  

For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.